Target intelligence / Profile preview

Bacterium

Molecular classification
Other (specifically, single-celled prokaryotic organisms, not a molecular target such as receptor, enzyme, transporter, etc.), "Gram-positive bacteria" (classification by cell wall structure), "Gram-negative bacteria" (classification by cell wall structure), Further classified into phyla such as Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, etc.[5][3][4]
01

Overview

Bacterium" is a generic term for microscopic, single-celled prokaryotic organisms that lack a membrane-bound nucleus, classified collectively as "Bacteria"—one of the three domains of life alongside Archaea and Eukarya. Bacteria exhibit immense diversity in morphology, physiology, and ecological roles. They are chiefly classified by features such as cell wall composition (Gram-positive or Gram-negative), shape (cocci, bacilli, spirilla), oxygen requirements (aerobes, anaerobes, etc.), and genetic characteristics. Bacteria play crucial roles in ecosystems (decomposition, nutrient cycling), inhabit all major environments (including human microbiota), and can cause a vast array of infectious diseases. Clinically, "bacterium" is not a therapeutic target itself; rather, specific bacteria (by genus/species/strain, or molecular component) are targets for antimicrobials, with drug mechanisms tailored to bacterial physiology. As an entry, "Various bacteria" is not a valid molecular or therapeutic target—information must specify a particular genus/species or molecular component for usefulness in research or drug development.[2][3][5] **Note:** - The term "Various bacteria" is too broad and nonspecific; it is not a molecular or therapeutic target but the name of a vast biological domain. - Canonical usage in pharmaceutical or biomedical context should specify a precise bacterial target (e.g., "Staphylococcus aureus", "DNA gyrase", "Penicillin-binding protein 2a") rather than "Various bacteria". - For structured data, deeper granularity is required. This entry is thus "incorrect" as a therapeutic target under the conventions provided.

Other names
BacteriaProkaryote (colloquial or descriptive, not exact)Eubacteria (outdated or specific subset)
02

Mechanism of action

- Inhibition of cell wall synthesis (e.g., beta-lactams, glycopeptides) - Inhibition of protein synthesis (e.g., tetracyclines, macrolides, aminoglycosides) - Inhibition of nucleic acid synthesis (e.g., fluoroquinolones, rifamycins) - Inhibition of folate synthesis (e.g., sulfonamides, trimethoprim) - Other mechanisms depending on bacterial target and antibiotic class[2]

03

Biological functions

Metabolism (e.g., fermentation, respiration)Environmental nutrient cycling (e.g., nitrogen fixation, decomposition)Pathogenesis in hostsCommensal/mutualistic roles in microbiotaOther (extensive, as bacteria occupy diverse biological niches)[2][5]
04

Disease associations

Infection (major role as pathogens in numerous infectious diseases)Other (commensal and probiotic roles; dysbiosis contributing to various conditions)[2][5]
05

Safety considerations

Bacterial antibiotic resistance (major global health threat)Opportunistic infection in immunocompromised hostsAdverse effects of disrupting normal microbiota (e.g., secondary infections like *Clostridioides difficile*, dysbiosis)[2]Endotoxin-mediated reactions (e.g., gram-negative sepsis)
06

Interacting drugs

Numerous drug classes, primarily:

9 more in the full profile.

07

Biomarkers

None universal ("bacterium" too broad); for specific bacteria, possible biomarkers could include antigens, DNA/RNA sequences, metabolic products, or antibiotic susceptibility profilesGram stain (for cell wall type)[5]16S rRNA gene sequences (for specific identification)[5][3]

Beyond the preview

Go deeper on Bacterium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call